Neumann Kristina, Terheyden Patrick, Thaçi Diamant
Exzellenzzentrum Entzündungsmedizin, Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland.
Klinik für Dermatologie, Allergologie und Venerologie, Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland.
Hautarzt. 2021 Nov;72(11):1000-1002. doi: 10.1007/s00105-021-04793-6. Epub 2021 Mar 24.
The case of a 32-year-old female with ulcerative colitis who developed severe papulopustular dermatitis while undergoing treatment with the Janus kinase (JAK) inhibitor tofacitinib. Despite intensive topical therapy, treatment with oral corticosteroids and oral doxycycline was unable to achieve sufficient improvement. Hence, tofacitinib treatment needed to be discontinued. It is well known that the class of JAK inhibitors can cause infectious and allergic cutaneous side effects. However, sterile papulopustular dermatitis as a side-effect has rarely been reported to date.
一名32岁患有溃疡性结肠炎的女性患者，在接受Janus激酶（JAK）抑制剂托法替布治疗时出现了严重的丘疹脓疱性皮炎。尽管进行了强化局部治疗，但口服皮质类固醇和口服强力霉素治疗仍未能取得足够的改善。因此，需要停用托法替布治疗。众所周知，JAK抑制剂类药物可引起感染性和过敏性皮肤副作用。然而，迄今为止，作为副作用的无菌性丘疹脓疱性皮炎很少被报道。
